Xenon Pharmaceuticals Inc. XENE
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. 10-K, Item 1
- Headquarters
- Burnaby
- CEO
- Ian Mortimer
- Next results
- around Feb 25, 2027
What changed
25 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 7 checks found nothing to note
-
Auditor change8-K item 4.01 (change in certifying accountant) filed Mar 5, 2025
-
Critical audit matters changedNew this year: External Research and Development Costs (“As described in Note 3 to the consolidated financial statements, research and development costs are expensed in the period incurred. Management recognizes research and development expenses using information and data provided by the vendors and third-party service providers. This process involves rev”)
-
Cash from operations −$279.1M vs net income −$345.9M (FY ending Dec 31, 2025)
6 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
25 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
We have no marketed proprietary products and are advancing clinical development through Phase 3 clinical studies for our azetukalner program in epilepsy, major depressive disorder, and bipolar depression. These studies may not result in regulatory approval or successful commercialization of our product candidates.
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
While we are advancing our Phase 3 clinical studies in azetukalner, significant risks remain. There can be no assurance that these or any future clinical studies will be successful, that we will be able to obtain regulatory approval, or that we will be able to manufacture or independently commercialize any product candidates. We may…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
Successful commercialization of any our current or future product candidates, if approved, could be materially adversely impacted by a number of foreseen and unforeseen factors, including: •any delays in our ability to produce sufficient quantities of or our current or future product candidates, at an acceptable cost or quality,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
In the U.S. in recent years, including under the current presidential administration, the pharmaceutical industry has been a particular focus of such reform efforts and has been significantly affected by major legislative, administrative and executive initiatives. For example, the Inflation Reduction Act (IRA) of 2022 includes a number…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $9.4M | $0 | $0 | $7.5M |
| Net income | −$125.4M | −$182.4M | −$234.3M | −$345.9M |
| Operating cash flow | −$101.0M | −$151.1M | −$181.4M | −$279.1M |
| Free cash flow | −$103.9M | −$156.7M | −$184.5M | −$279.9M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$7.5M in FY2025−$345.9M in FY2025−$279.9M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 9, 2026Ian Mortimer (President and Chief Executive Officer) adopted a trading plan reported in the 10-Q
-
Planned saleNov 9, 2026Thomas P. Kelly (Chief Financial Officer) adopted a trading plan reported in the 10-Q
-
8-KNov 9, 2026Quarterly results, Regulation FD disclosure 8-K items 2.02, 7.01
-
10-QNov 9, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Xenon Pharmaceuticals Inc., Burnaby · from the 10-K filed Feb 26, 2026
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.
- Headquarters
- Burnaby
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 9, 2026
- Incorporated in
- British Columbia, Canada
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XENE/export.csv") into a cell.